Overview
Megaconial congenital muscular dystrophy encompasses severe forms such as Walker-Warburg syndrome (WWS), Fukuyama-type congenital muscular dystrophy (FCMD), and muscle-eye-brain (MEB) disease, characterized by congenital muscular dystrophy, cobblestone lissencephaly, and ocular anomalies 123. WWS represents the most severe phenotype within this spectrum 1.Diagnosis
Clinical Presentation: Generalized hypotonia, muscle weakness, developmental delay, mental retardation, seizures, and characteristic brain and eye abnormalities 2.
Laboratory Tests: Elevated creatine kinase levels, myopathic/dystrophic muscle pathology, and altered alpha-dystroglycan 2.
Genetic Testing: Mutations in genes such as POMT1, POMT2, Fukutin, and FKRP are implicated; specific mutations can differentiate between FCMD and WWS 12.
Imaging: MRI showing type II cobblestone lissencephaly, hydrocephalus, cerebellar malformations, and brain dysmorphisms 26.
Ophthalmic Evaluation: Presence of cataracts, retinal detachment, and other ocular anomalies 57.
Pathology: Muscle biopsy showing dystrophic changes and hypoglycosylation of alpha-dystroglycan 2.Management
Supportive Care: Respiratory support, nutritional management, and physical therapy to maintain muscle function and prevent complications 2.
Seizure Control: Anticonvulsant medications as needed for seizure management 2.
Hydrocephalus Management: Surgical interventions such as shunting for hydrocephalus 2.
Ophthalmic Interventions: Cataract surgery and management of retinal detachment 57.
Genetic Counseling: Provided to families for understanding inheritance patterns and recurrence risks 2.
Multidisciplinary Approach: Collaboration among neurologists, ophthalmologists, geneticists, and physical therapists 2.Special Populations
Pediatrics: Early intervention is crucial for managing symptoms and improving quality of life 2.
Comorbidities: Respiratory failure and feeding difficulties are common, requiring intensive supportive care 27.Key Recommendations
Genetic Testing for Diagnosis: Identify causative mutations in POMT1, POMT2, Fukutin, and FKRP to differentiate between FCMD and WWS (Evidence: Strong 12).
Comprehensive Imaging: Utilize MRI to assess brain malformations including lissencephaly and hydrocephalus for accurate diagnosis (Evidence: Moderate 26).
Multidisciplinary Support: Implement a multidisciplinary team approach including neurology, ophthalmology, and physical therapy to manage symptoms and improve outcomes (Evidence: Expert opinion 2).References
1 Yoshioka M. Phenotypic spectrum of Fukutinopathy: most severe phenotype of Fukutinopathy. Brain & development 2009. link
2 Vajsar J, Schachter H. Walker-Warburg syndrome. Orphanet journal of rare diseases 2006. link
3 Voit T. Congenital muscular dystrophies: 1997 update. Brain & development 1998. link00094-6)
4 Yamamoto T, Shibata N, Kanazawa M, Kobayashi M, Komori T, Ikeya K et al.. Localization of laminin subunits in the central nervous system in Fukuyama congenital muscular dystrophy: an immunohistochemical investigation. Acta neuropathologica 1997. link
5 Sanders DG, Mooy CM. Ocular findings in cerebro-ocular-myopathy syndrome (COMS). A possible role of growth factors?. International ophthalmology 1993. link
6 Kimura S, Sasaki Y, Kobayashi T, Ohtsuki N, Tanaka Y, Hara M et al.. Fukuyama-type congenital muscular dystrophy and the Walker-Warburg syndrome. Brain & development 1993. link90063-e)
7 Wargowski DS, Chitayat D, Tyson RW, Norman MG, Friedman JM. Lethal congenital muscular dystrophy with cataracts and a minor brain anomaly: new entity or variant of Walker-Warburg syndrome?. American journal of medical genetics 1991. link
8 Matsumura K, Shimizu T, Sunada Y, Mannen T, Nonaka I, Kimura S et al.. Degradation of connectin (titin) in Fukuyama type congenital muscular dystrophy: immunochemical study with monoclonal antibodies. Journal of the neurological sciences 1990. link90256-m)
9 Towfighi J, Sassani JW, Suzuki K, Ladda RL. Cerebro-ocular dysplasia-muscular dystrophy (COD-MD) syndrome. Acta neuropathologica 1984. link